BMO Capital Markets reiterated coverage on BioNTech
$BNTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BMO Capital Markets reiterated coverage of BioNTech with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $145.00 | Buy | Citigroup |
| 1/10/2025 | $172.00 | Buy | Truist |
| 12/11/2024 | $170.00 | Overweight | Wells Fargo |
| 12/2/2024 | Outperform | BMO Capital Markets | |
| 11/19/2024 | $130.00 | Buy | Berenberg |
| 11/19/2024 | $110.00 → $125.00 | In-line → Outperform | Evercore ISI |
| 11/8/2024 | $90.00 → $137.00 | Neutral → Buy | Goldman |
| 9/24/2024 | $93.00 → $145.00 | Equal-Weight → Overweight | Morgan Stanley |
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapies Multiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech's pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030 Completed acquisition of Biotheus securing full control of next-generation immunomodulator candidate BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1 Successfully launched JN.1- and KP.2-adapted COVID-19 vaccines across different coun
MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast wil
Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodiesBiotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company's network MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today the completion of the acquisition
Citigroup initiated coverage of BioNTech with a rating of Buy and set a new price target of $145.00
Truist initiated coverage of BioNTech with a rating of Buy and set a new price target of $172.00
Wells Fargo initiated coverage of BioNTech with a rating of Overweight and set a new price target of $170.00
20-F - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13D - BioNTech SE (0001776985) (Filed by)
SC 13G/A - BioNTech SE (0001776985) (Subject)
Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumorsWith the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinationsBioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 202
MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S. On the day, BioNTech's leadership team will provide an overview of the Company's corporate strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one yea
Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from Novartis AG ("Novartis") and succeed Sean Marett in this role. Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access. In her new role, she will drive and execute the global commercialization strategy to leverage BioNTech's full potential as a verticall
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapies Multiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech's pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030 Completed acquisition of Biotheus securing full control of next-generation immunomodulator candidate BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1 Successfully launched JN.1- and KP.2-adapted COVID-19 vaccines across different coun
MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast wil
Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech's FixVac platform Initiated two Phase 2 dose optimization trials with BNT327/PM8002 in small-cell lung cancer and in triple-negative breast cancer to inform planned pivotal Phase 3 trialsPhase 2 clinical trial on track to evaluate mRNA-based individualized cancer vaccine candidate autogene cevumeran (BNT122/RO7198457) as an adjuvant treatment in patients with high-risk muscle-invasive urothelial cancerSuccessfully launched variant-adapted COVID-19 vaccines for the 2024/2025 vaccination season in multiple regionsReports